top of page
M&A Activity
Covers mergers and acquisitions where in vitro technology developers are either the acquirer or the acquired
InSphero expands its high-content imaging capabilities with acquisition of PhenoVista Biosciences
20 May 2026 Zurich-based CRO InSphero, global leader in advanced 3D in vitro products and services, announces the acquisition of PhenoVista Biosciences to expand its high-content imaging and phenotypic analysis capabilities for drug discovery and safety testing. San Diego-based CRO PhenoVista Biosciences, Inc., is a leading provider in high-content imaging, cell painting, and functional cellular analysis for the biopharmaceutical industry. Their diverse repertoire includ
Axol Bioscience acquires ophthalmology business from Newcells Biotech
18 February 2026 Edinburgh-based CRO Axol Bioscience, leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, announces that it has acquired the ophthalmology business of the Newcastle-based CRO Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services. Devel
bottom of page